Comparison of anticancer effects of everolimus-gemcitabine combination with gemcitabine on pancreatic cancer using Rgs16 biomarker evaluation

This study showed that a combination of everolimus and gemcitabine is more potent than everolimus, which is more effective than gemcitabine, in killing pancreatic cancer cells. However,Rgs16 as a marker of invasion was very low in Panc-1 cells and the drugs were not effective in alteringRgs16 gene expression or protein level. Although this may suggest that Panc-1 is a very invasive cell line and these drugs are not effective in highly metastatic cases, the cell line might be resistant toRgs16 expression due to its specific mutations.
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research